Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-008 Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Announcement on the appointment of senior vice president of the company
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as “the company”) held the 21st Meeting of the first board of directors on January 19, 2022, deliberated and approved the proposal on the appointment of senior vice president of the company, agreed to appoint Ms. Zhang Jing and Mr. Hong Qi as senior vice president of the company, and Mr. Hong Qi as chief technical officer of the company at the same time (see the annex for relevant resumes), The term of office starts from the date of deliberation and approval of the current board of directors to the date of expiration of the term of office of the first board of directors.
The independent directors of the company have expressed their independent opinions on the appointment of the above senior vice presidents and believe that the procedures for the appointment of Ms. Zhang Jing and Mr. Hong Qi as senior managers of the company comply with the relevant provisions of the company law and the articles of association, and have not found that the above personnel are not suitable for serving as senior managers of the company. As of the disclosure date of this announcement, Ms. Zhang Jing and Mr. Hong Qi do not directly hold the company’s shares, have no relationship with the company’s controlling shareholders, actual controllers, directors, supervisors, senior managers and shareholders holding more than 5% of the company’s shares, and are not prohibited from serving as senior managers of the company according to the company law and other laws and regulations, Nor has it been punished by the CSRC and other relevant departments or by the stock exchange.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of directors January 20, 2022
enclosure:
1、 Resume of Ms. Zhang Jing
Zhang Jing, female, Chinese nationality, without overseas residency, was born in October 1967 and graduated from Wuhan University of science and technology in clinical medicine. Ms. Zhang Jing China China China has been working in January 2007 from December 2021 to December 2021, and has been the director of China’s antivirus division, director of strategy and innovation division, responsible for the listing and operation of China’s anti aids products in China, and the construction of eco chain and the expansion of innovation business in China. Previously, Ms. Zhang served as the regional manager of Schering plough, the regional manager of Abbott pharmaceutical East 1, the government affairs manager, etc.
2、 Resume of Mr. Hong Qi
Hong Qi, male, British nationality, born in January 1963, graduated from the Department of chemistry of Nanjing University with a bachelor’s degree, a doctor of chemistry, and a postdoctoral fellow of Oxford University, UK. Mr. Hong Qi has served as associate researcher of Institute of cell and Molecular Life Sciences, School of medicine, University of Newcastle, UK, senior researcher of human genetics research center, University of Oxford, senior researcher, research director and chief scientist of DDS (discovery and development solutions) Department of Merck group in UK. From April 2013 to January 2018, Mr. Hong Qi joined Xiansheng pharmaceutical and baijiahui biology as the executive technical director, responsible for the evaluation and quality analysis of biomacromolecule drugs; From February 2018 to December 2021, he served as a consultant for Biomacromolecule analysis and quality research. Mr. Hong Qi has been engaged in the research and development of chemical and biological drugs for more than 20 years, published more than 50 SCI professional papers, led and participated in the research and development of nearly 30 biological macromolecular drugs, and won the third prize of the National Natural Science Award of the people’s Republic of China and the second prize of the science and technology progress award of the National Education Commission.
